SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.

Plus: Korea's Dong Wha readies potent antiviral for trials, and Pharming's candidate shows promise in compassionate use.

The US Veterans Administration is attracting more interest from drugmakers seeking to grow their foothold in the lucrative – but scientifically challenging – market for CNS disorders. The allure comes from VA’s strong analytics and data crunching capabilities as well as its investigatory and trial management expertise in high-profile areas like traumatic brain injury, post-traumatic stress and major depression.

The Netherlands-based biomaterials start-up intends to expand its platform's reach through strategic partnerships and tuck-in acquisitions.